Literature DB >> 28769452

A STUDY OF SUPERIOR VENA CAVA OBSTRUCTION SYNDROME.

Deepak Rosha1, P K Dandona1.   

Abstract

Superior vena cava obstruction syndrome was studied in 22 patients with a view to assess the etiological pattern and clinical profile. It was found that 4 patients (18.1%) had benign disease and the remaining 18 (81.9%) patients had malignancy. In 13 patients (59.9%) obstruction occurred due to bronchogenic carinoma. No complications occurred with invasive diagnostic procedures. All heavy smokers (59.9%) were found to have malignancy. Normal lung fields on chest radiography and CT scan with superior vena obstruction syndrome suggested benign disease in 2 cases.

Entities:  

Keywords:  Bronchogenic carcinoma; Mediastinum; Superior vena cava syndrome

Year:  2017        PMID: 28769452      PMCID: PMC5530844          DOI: 10.1016/S0377-1237(17)30674-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  6 in total

1.  Superior vena cava syndrome. Clinical management.

Authors:  R Goodman
Journal:  JAMA       Date:  1975-01-06       Impact factor: 56.272

2.  Superior vena cava obstruction: clinical syndrome, etiology, and treatment.

Authors:  A F Nieto; D B Doty
Journal:  Curr Probl Cancer       Date:  1986-09       Impact factor: 3.187

3.  Study of superior vena cava syndrome--aetiopathology, diagnosis and management.

Authors:  B O Tayade; S S Salvi; I R Agarwal
Journal:  J Assoc Physicians India       Date:  1994-08

4.  Investigation of superior vena caval obstruction.

Authors:  A Allan; B Sethia; K G Davidson
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

5.  Superior vena cava syndrome in childhood: report of ten cases and review of the literature.

Authors:  P Y Issa; E R Brihi; Y Janin; M S Slim
Journal:  Pediatrics       Date:  1983-03       Impact factor: 7.124

6.  Superior vena cava syndrome. The myth--the facts.

Authors:  A Yellin; A Rosen; N Reichert; Y Lieberman
Journal:  Am Rev Respir Dis       Date:  1990-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.